MEDRELEAF CORP COM NPV (OTCMKTS:MEDFF) Is A Marijuana Stock Runner

The past year has been glorious for the shareholders and management of Medreleaf Corp (OTCQB:MEDFF).They held the first cannabis company IPO in Canada where they raised over $75 million after which their revenues went up by over 109% in the period following the IPO. MEDFF has stayed focused on growing its brand in Canada and more recently venturing into the rest of the world; all which have led to the surge in its share price.As seen in the chart below, the company’s share price is seen to trend upwards: MEDFF Daily ChartThis piece will review the stock, assessing its potential upside based on its strategy and financial performance. We want to bring out our view on the benefits accruing to an investor investing in this stock for either the short or long term.Having said this, it is important for us to briefly review the company for readers with rudimentary knowledge of its operations.Medreleaf Corp: An OverviewMedReleaf is a Health Canada Licensed Producer, and the first and only ISO 9001 certified medical cannabis producer in North America. The company was founded in 2013 and incorporated in Canada. MedReleaf is a R&D driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis. The company has since inception built on its strong brand to grow within Canada as well as venture into new markets such as Brazil where it made its first export to in August 2017.With their robust network and strong brand, they are on a growth trajectory that is in line with their recent history as will be seen in their financial analysis.History and futureMEDFF has in the past made significant leaps that have pivoted it to the giant it currently is. Earlier this year, they announced and completed its first IPO, the first cannabis company in the world to complete such a venture in which they raised over $75 million. This, despite criticism in Canada, was no mean feat.The company further went on to silence its critics with its first export to Brazil in August 2017. This was in a bid to treat the symptoms of Sofia Langenbach, a child who carries the CDKL5 genetic syndrome – leading her to experience refractory epilepsy and severe seizures which for her, has only been alleviated by the use of medical cannabis.Neil Closner, CEO of MedReleaf, was quoted saying:

"We have been working with Margarette Santos De Brito (president of Brazilian NGO APEPI), who has been a tireless, high-profile public champion of medical cannabis and whose daughter Sofia is in dire need of cannabis-based pharmaceutical products to manage her symptoms.We are proud that Ms. Santos and ANVISA, the Brazilian Government's National Health Surveillance Agency, have put their faith in MedReleaf."

Source:The company went further to seal a deal with Flora Fotonica Ltdto invest and collaborate on the research and development of specialized grow lighting systems for cannabis cultivation. Flora Fotonica will, in future, provide MedReleaf with exclusive access to its proprietary LED lighting technology and MedReleaf will dedicate licensed growing space, laboratories, and research personnel.Finally, they have been included in the North American Marijuana Index, a move which their Chief Executive dubbed “A recognition of our position as one of the industry's largest and most respected cannabis producers.”Source:These all speak to the promising outlook the company has as well as their growth potential. It would be prudent therefore to assess how much resources they have amassed to enable them to build the future they envision.Financial MuscleAs earlier stated, the company has been enjoying significant growth in its numbers over the recent past. MEDFF has seen its market cap grow to $804,156,287 and keep rising by the day. The stock has consistently maintained an upward trend and is poised to continue in the same trend into the future.Their revenues rose from $19,302,000 in the period till March 2016 to $40,339,000 in the period till March 2017, a 109% annual increase. This marked one of the highest increases in revenues in the cannabis industry over this period. In a deeper analysis, for the quarter till June 2017, their revenues grew to $10,416,000 from $8,804,000, a 19% year-on-year growth rateanalysis. This was due to the inclusion of extracts from cannabis in their portfolio of products which added about $1.5 million to its revenues. Their diverse portfolio is bound to boost their revenues into the distant future.The company also prides itself in taking part in ground-breaking research and development projects. Over this period, their research and development costs rose from $217,000 to $382,000. This increase is taken to be a significant investment into the future of the company which bases its growth on finding futuristic solutions to current and anticipated problems.Finally, in the quarter to June 2017, their net income rose by over four times to $10,958 from $2,531. The company, as seen above, is growing at a high rate and given that this is expected to continue into the future, it will be a solid investment as the potential upside exuded above is bound to continue to even greater levels.ConclusionMEDFF is a story of shear willpower and vision as the company took advantage of its fast mover position to secure a footing at the throne of the cannabis industry. They are expected to grow even further as we move into the future and serve as a good bet for investors who are looking to retire early.We will be updating our subscribers as soon as we know more. For the latest updates on MEDFF, sign up below!Image courtesy of Lloyd Barnes via FlickrDisclosure: We have no position in MEDFF and have not been compensated for this article.